Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
A8K979

UPID:
ERI2_HUMAN

ALTERNATIVE NAMES:
Exonuclease domain-containing protein 1

ALTERNATIVE UPACC:
A8K979; Q6ZSJ2; Q96FR9; Q9P224; Q9Y6V3

BACKGROUND:
The protein ERI1 exoribonuclease 2, alternatively known as Exonuclease domain-containing protein 1, is integral to the regulation of RNA interference and turnover. Its exploration is vital for elucidating the complexities of RNA biology and its impact on cellular functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ERI1 exoribonuclease 2 holds the potential to revolutionize therapeutic approaches. As research progresses, its significance in RNA-mediated processes may provide novel insights into targeting diseases at the molecular level.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.